These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 35466424)

  • 1. Stability of serial platelet and urine protein measurements in patients receiving nusinersen for spinal muscular atrophy.
    Nagarajan EK; Özütemiz C; Rubin N; Nascene DR
    Muscle Nerve; 2022 Jul; 66(1):76-79. PubMed ID: 35466424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety analysis of laboratory parameters in paediatric patients with spinal muscular atrophy treated with nusinersen.
    Zhu X; Li H; Hu C; Wu M; Zhou S; Wang Y; Li W
    BMC Pediatr; 2024 Jul; 24(1):474. PubMed ID: 39054521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden.
    Zuluaga-Sanchez S; Teynor M; Knight C; Thompson R; Lundqvist T; Ekelund M; Forsmark A; Vickers AD; Lloyd A
    Pharmacoeconomics; 2019 Jun; 37(6):845-865. PubMed ID: 30714083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study.
    Hagenacker T; Wurster CD; Günther R; Schreiber-Katz O; Osmanovic A; Petri S; Weiler M; Ziegler A; Kuttler J; Koch JC; Schneider I; Wunderlich G; Schloss N; Lehmann HC; Cordts I; Deschauer M; Lingor P; Kamm C; Stolte B; Pietruck L; Totzeck A; Kizina K; Mönninghoff C; von Velsen O; Ose C; Reichmann H; Forsting M; Pechmann A; Kirschner J; Ludolph AC; Hermann A; Kleinschnitz C
    Lancet Neurol; 2020 Apr; 19(4):317-325. PubMed ID: 32199097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nusinersen improved respiratory function in spinal muscular atrophy type 2.
    Tanaka R; Fukushima F; Motoyama K; Kobayashi C; Izumi I
    Pediatr Int; 2021 Aug; 63(8):973-974. PubMed ID: 34245199
    [No Abstract]   [Full Text] [Related]  

  • 6. Analysis of the efficacy and adverse effects of nusinersen in the treatment of children with spinal muscular atrophy in China.
    Li D; Yang J; Wang X; Yang L; Luo R; Huang S
    Brain Behav; 2024 Jul; 14(7):e3630. PubMed ID: 39034388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy.
    Pechmann A; Behrens M; Dörnbrack K; Tassoni A; Stein S; Vogt S; Zöller D; Bernert G; Hagenacker T; Schara-Schmidt U; Schwersenz I; Walter MC; Baumann M; Baumgartner M; Deschauer M; Eisenkölbl A; Flotats-Bastardas M; Hahn A; Horber V; Husain RA; Illsinger S; Johannsen J; Köhler C; Kölbel H; Müller M; von Moers A; Schlachter K; Schreiber G; Schwartz O; Smitka M; Steiner E; Stögmann E; Trollmann R; Vill K; Weiß C; Wiegand G; Ziegler A; Lochmüller H; Kirschner J;
    Brain; 2023 Feb; 146(2):668-677. PubMed ID: 35857854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.
    Finkel RS; Chiriboga CA; Vajsar J; Day JW; Montes J; De Vivo DC; Yamashita M; Rigo F; Hung G; Schneider E; Norris DA; Xia S; Bennett CF; Bishop KM
    Lancet; 2016 Dec; 388(10063):3017-3026. PubMed ID: 27939059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammatory markers in cerebrospinal fluid of paediatric spinal muscular atrophy patients receiving nusinersen treatment.
    Scheijmans FEV; Cuppen I; Zwartkruis MM; Signoria I; van Ekris C; Asselman F; Wadman RI; Knol EF; van der Pol WL; Groen EJN
    Eur J Paediatr Neurol; 2023 Jan; 42():34-41. PubMed ID: 36525882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nusinersen for older patients with spinal muscular atrophy: A real-world clinical setting experience.
    Veerapandiyan A; Eichinger K; Guntrum D; Kwon J; Baker L; Collins E; Ciafaloni E
    Muscle Nerve; 2020 Feb; 61(2):222-226. PubMed ID: 31773738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nusinersen treatment in a type 3 spinal muscular atrophy patient during early pregnancy.
    Schön M; Domingues S; de Carvalho M; Oliveira Santos M
    Neurol Sci; 2023 May; 44(5):1803-1804. PubMed ID: 36645532
    [No Abstract]   [Full Text] [Related]  

  • 12. Changes in pNFH Levels in Cerebrospinal Fluid and Motor Evolution after the Loading Dose with Nusinersen in Different Types of Spinal Muscular Atrophy.
    Badina M; Bejan GC; Sporea C; Padure L; Mirea A; Leanca MC; Axente M; Grigoras FP; Bejan M; Shelby ES; Neagu E; Ion DA
    Medicina (Kaunas); 2023 Jul; 59(7):. PubMed ID: 37512056
    [No Abstract]   [Full Text] [Related]  

  • 13. Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis.
    Gauthier-Loiselle M; Cloutier M; Toro W; Patel A; Shi S; Davidson M; Bischof M; LaMarca N; Dabbous O
    Adv Ther; 2021 Dec; 38(12):5809-5828. PubMed ID: 34713391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nusinersen treatment in adult patients with spinal muscular atrophy: a safety analysis of laboratory parameters.
    Stolte B; Nonnemacher M; Kizina K; Bolz S; Totzeck A; Thimm A; Wagner B; Deuschl C; Kleinschnitz C; Hagenacker T
    J Neurol; 2021 Dec; 268(12):4667-4679. PubMed ID: 33899154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of nusinersen treatment on respiratory status of children with spinal muscular atrophy.
    Hepkaya E; Kılınç Sakallı AA; Ülkersoy İ; Başkan AK; Arslan H; Meral Ö; Dilek TD; Güler S; Saltık S; Çokuğraş H
    Pediatr Int; 2022 Jan; 64(1):e15310. PubMed ID: 36310036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laboratory monitoring of nusinersen safety.
    Goedeker NL; Gibbons JL; Varadhachary AS; Connolly AM; Zaidman CM
    Muscle Nerve; 2021 Jun; 63(6):902-905. PubMed ID: 33675054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study.
    Acsadi G; Crawford TO; Müller-Felber W; Shieh PB; Richardson R; Natarajan N; Castro D; Ramirez-Schrempp D; Gambino G; Sun P; Farwell W
    Muscle Nerve; 2021 May; 63(5):668-677. PubMed ID: 33501671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical efficacy of nusinersen sodium in the treatment of children with spinal muscular atrophy].
    Guo J; Wu YH; Zhang LX; Ji HR; Zhou N; Hu XY
    Zhongguo Dang Dai Er Ke Za Zhi; 2024 Jul; 26(7):743-749. PubMed ID: 39014952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retrospective cohort study of children with spinal muscular atrophy type 2 receiving anesthesia for intrathecal administration of nusinersen.
    Bielsky AR; Fuhr PG; Parsons JA; Yaster M
    Paediatr Anaesth; 2018 Dec; 28(12):1105-1108. PubMed ID: 30284761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unveiling the adverse events of Nusinersen in spinal muscular atrophy management based on FAERS database.
    Jiang Y; Shen Y; Zhou Q; Zhu H
    Sci Rep; 2024 Jul; 14(1):17138. PubMed ID: 39060346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.